Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
John W. Eikelboom, Sanjit S. Jolly, Emilie P. Belley‐Côté, Richard Whitlock, Sumathy Rangarajan, Lizhen Xu, Laura Heenan, Shrikant I. Bangdiwala, Marı́a Luz Dı́az, Rafael Díaz, Afzalhussein Yusufali, Sanjib Kumar Sharma, Wadea Tarhuni, Mohamed Hassany, Álvaro Avezum, William Harper, Sean Wasserman, Aysha Almas, Oxana M. Drapkina, Camilo Félix, Renato D. Lópes, Otávio Berwanger, Patricio López‐Jaramillo, Sonia S. Anand, Jackie Bosch, Shurjeel Choudhri, Michael E. Farkouh, Mark Loeb, Salim Yusuf
Topics & Concepts
MedicineRivaroxabanAspirinRandomized controlled trialPopulationInternal medicinePulmonary embolismStroke (engine)HydroxychloroquineCOPDDiseaseCoronavirus disease 2019 (COVID-19)WarfarinInfectious disease (medical specialty)Mechanical engineeringEnvironmental healthEngineeringAtrial fibrillationCOVID-19 Clinical Research StudiesDermatological and COVID-19 studiesInflammasome and immune disorders